Background
Phase II, open-label, single-arm study. 34 patients with newly diagnosed T follicular helper (TFH) cell lymphoma subtype (angioimmunoblastic T-cell lymphoma [AITL], follicular T-cell lymphoma, and PTCL-NOS with TFH phenotype), plus a separate cohort of 18 non-TFH PTCL patients. TFH-phenotype PTCL is enriched for IDH2 and TET2 epigenetic mutations (TET2 in ~80%), providing biologic rationale for DNA hypomethylating agents. CC-486 (oral azacitidine) was combined with standard CHOP as frontline therapy.
Interventions and follow up
Regimen: Oral azacitidine (CC-486) 300 mg PO days 1–7 + CHOP every 21d × 6 cycles in newly diagnosed PTCL (TFH/AITL phenotype cohort)
Primary endpoint: Complete response rate after 6 cycles (TFH cohort)
Median follow up: 22 months
Primary endpoint: Complete response rate after 6 cycles (TFH cohort)
Median follow up: 22 months
Results
CR rate (TFH cohort, primary): 88.2% (30/34)
ORR: 94.1%
2-year PFS: 69.2%
2-year OS: 76.1%
TET2-mutated patients: CR rate 100% (15/15); significantly better PFS (HR 0.21, P=.004) and OS vs TET2-wild type
Non-TFH PTCL cohort CR: 66.7%
ORR: 94.1%
2-year PFS: 69.2%
2-year OS: 76.1%
TET2-mutated patients: CR rate 100% (15/15); significantly better PFS (HR 0.21, P=.004) and OS vs TET2-wild type
Non-TFH PTCL cohort CR: 66.7%
Adverse events
Hematologic: Grade ≥3 neutropenia 64.7%; febrile neutropenia 29.4%; grade ≥3 thrombocytopenia 23.5%
Infection/overall: Grade ≥3 infections 17.6%; grade ≥3 AEs 88.2% (TFH cohort); three treatment-related deaths (sepsis)
Infection/overall: Grade ≥3 infections 17.6%; grade ≥3 AEs 88.2% (TFH cohort); three treatment-related deaths (sepsis)
Conclusions
CC-486 + CHOP achieved exceptionally high CR rates (88.2%) in TFH-phenotype PTCL, particularly in TET2-mutated AITL (100% CR). This provides strong proof-of-concept for epigenetic priming in AITL, with TET2 mutation as a predictive biomarker of response.
Key Limitations
Single-arm phase II with small cohorts (34 TFH, 18 non-TFH) and no randomized comparison to CHOP alone, so the relative contribution of CC-486 cannot be isolated. Short median follow-up (22 months) limits durability assessment. Three treatment-related sepsis deaths underscore added myelosuppression. Biomarker findings (TET2) are exploratory and require prospective validation.
Clinical Context
CC-486 + CHOP is not FDA/EMA approved for PTCL; these data are hypothesis-generating and support the randomized phase III ALLIANCE/intergroup trial (oral azacitidine + CHOP vs CHOP) in TFH-phenotype PTCL. ASCO and ESMO guidance still favor CHOP/CHOEP-based frontline therapy for nodal TFH lymphomas, with epigenetic combinations remaining investigational.